Canada recommends giving "Johnson & Johnson" vaccine to people over 30 years old

On Monday, a Canadian government advisory committee recommended that the "Johnson & Johnson" anti-corona virus vaccine be given to people over the age of 30, despite fears of blood clots.

In March, the Canadian Ministry of Health allowed the vaccine to be used for all adults, but the doses have not yet been given, and the authorities have not given the green light to distribute the first shipment of 300,000 doses due to quality issues.

Shali Dix of the National Advisory Committee on Immunization in Canada said that the "Johnson & Johnson" vaccine has proven "very effective" in preventing severe Covid infection.

But it acknowledged the existence of blood clots related to this vaccine, referring to 17 cases out of 8 million people who received the vaccine.

"The messenger RNA vaccines (such as Pfizer and Moderna) are preferred," Dicks said at a press conference, adding that "Virus vaccines (Johnson & Johnson and AstraZeneca) are very effective vaccines, but there are safety risks."

"Although problems are rare, they are very dangerous," she said, noting that individuals need to "knowingly choose to be vaccinated with the first available vaccine or wait for the messenger RNA vaccine."

According to AFP statistics, the "Johnson & Johnson" vaccine is used in 17 countries, including France, South Africa, the United States, Spain, Germany and Poland.

And Denmark announced on Monday that it would not use the "Johnson & Johnson" vaccine in its national vaccination campaign, citing concerns about serious side effects, including blood clots.

Canada contracted to receive 10 million doses of the Johnson & Johnson vaccine, with an option to order 28 million additional doses.

On Friday, it announced that it was withholding the first batch of 300,000 doses it received for further quality assurance checks.

Follow our latest local and sports news, and the latest political and economic developments via Google news